Table 1 Comparison of baseline characteristics of patients with prior negative prostate biopsy (n = 251) according to the presence of visible lesions (PI-RADSv2 ≥ 3) on multiparametric magnetic resonance imaging.
Variables | Overall | Invisible MRI lesion (PI-RADSv2 < 3) | Visible MRI lesion (PI-RADSv2 ≥ 3) | p value |
|---|---|---|---|---|
Number of patients, n (%) | 251 (100.0%) | 124 (49.4%) | 127 (50.6%) | |
Age, yr | 64.7 ± 8.5 | 62.9 ± 8.1 | 66.4 ± 8.5 | 0.001* |
DRE abnormality, n (%) | 7 (2.8%) | 4 (3.2%) | 3 (2.4%) | 0.678 |
Prostate volume, mL | 48.0 ± 22.0 | 50.0 ± 22.4 | 46.1 ± 21.4 | 0.164 |
PSA, ng/mL | 8.44 ± 7.78 | 6.82 ± 5.39 | 10.02 ± 9.31 | 0.001* |
PSAD, ng/mL2 | 0.21 ± 0.22 | 0.15 ± 0.11 | 0.26 ± 0.28 | < 0.001* |
%fPSA, % | 19.59 ± 12.97 | 20.16 ± 10.31 | 19.02 ± 15.14 | 0.485 |
PI-RADSv2 score, n (%) | ||||
3 | 44 (34.6%) | |||
4 | 52 (40.9%) | |||
5 | 31 (24.4%) | |||
Location of MRI lesion, n (%) | ||||
Transitional zone | 65 (51.2%) | |||
Peripheral zone | 50 (39.4%) | |||
Both | 10 (7.9%) | |||
Unknown | 2 (1.6%) | |||
Laterality of MRI lesion, n (%) | ||||
Unilateral | 114 (89.8%) | |||
Bilateral | 13 (10.2%) | |||
Method of PB, n (%) | ||||
Systematic 12-core PB | 126 (50.2%) | 124 | 2 (1.6%) | |
MRI-targeted + systematic 12-core PB | 125 (49.8%) | 0 | 125 (98.4%) | |
Number of PB | 13.37 ± 1.11 | 12.78 ± 1.04 | 13.95 ± 0.84 | < 0.001 * |
Number of MRI-targeted biopsy | 2.08 ± 0.47 | |||
Patients with overall PB (n = 251) | ||||
Benign | 162 (64.5%) | 85 (68.5%) | 77 (60.6%) | |
≤ GS 6 | 42 (16.7%) | 21 (16.9%) | 21 (16.5%) | 0.231 |
≥ GS 7 (3 + 4) | 47 (18.7%) | 18 (14.5%) | 29 (22.8%) | |
Patients with systematic 12-core PB (n = 251) | ||||
Benign | 171 (68.1%) | 99 (79.8%) | 72 (56.7%) | |
≤ GS 6 | 40 (15.9%) | 19 (15.3%) | 21 (16.5%) | < 0.001* |
≥ GS 7 (3 + 4) | 40 (15.9%) | 6 (4.8%) | 34 (26.3%) | |
Patients with MRI-targeted biopsy (n = 125) | ||||
Benign | 81 (64.8%) | |||
≤ GS 6 | 11 (8.8%) | |||
≥ GS 7 (3 + 4) | 33 (26.4%) | |||
